The resistance of the cirrhotic liver: A new target for the treatment of portal hypertension - A commentary

Journal of Hepatology

Volumn 40, Issue 6, 2004, Pages 887-890

  García Pagán, Juan Carlos ^a   Bosch, Jaume ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; BUFFER; CARBON TETRACHLORIDE; CYTOCHALASIN B; ISOPRENALINE; LEUKOTRIENE; MAGNESIUM SULFATE; NITROPRUSSIDE SODIUM; NORADRENALIN; PAPAVERINE DERIVATIVE; PROSTAGLANDIN E1; THROMBOXANE A2; VASODILATOR AGENT;

ANIMAL TISSUE; BLOOD VESSEL TONE; CONTROLLED STUDY; IN VITRO STUDY; ISOLATED LIVER; LIVER CIRRHOSIS; LIVER DISEASE; MYOFIBROBLAST; NONHUMAN; NOTE; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN; PRIORITY JOURNAL; RAT; UREA CYCLE;

ANIMALS; HISTORY, 20TH CENTURY; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; RATS;

EID: 2442671360     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(04)00137-0     Document Type: Note

References (23)

1. Vorobioff J., Bredfeldt J.E., Groszmann R.J. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 244:1983;G52-G57
2. Vorobioff J., Bredfeldt J.E., Groszmann R.J. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology. 87:1984;1120-1126
3. Sikuler E., Groszmann R.J. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol. 250:1986;G205-G212
4. Sikuler E., Kravetz D., Groszmann R.J. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol. 248:1985;G618-G625
5. Bhathal P.S., Grossman H.J. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1:1985;325-337
6. Groszmann R.J., Bosch J., Grace N.D., Conn H.O., Garcia-Tsao G., Navasa M., et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage (see comments). Gastroenterology. 99:1990;1401-1407
7. Feu F., Garcia-Pagan J.C., Bosch J., Luca A., Teres J., Escorsell A., et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 346:1995;1056-1059
8. Escorsell A., Bordas J.M., Castaneda B., Llach J., Garcia-Pagan J.C., Rodes J., et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 31:2000;1061-1067
9. Villanueva C., Balanzo J., Novella M.T., Soriano G., Sainz S., Torras X., et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 334:1996;1624-1629
10. Abraldes J.G., Tarantino I., Turnes J., Garcia-Pagan J., Rodes J., Bosch J. Hemodynamic response to pharmacologic treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 37:2003;902-908
11. Kaneda K., Ekataksin W., Sogawa M., Matsumura A., Cho A., Kawada N. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology. 27:1998;735-747
12. Zhang J.X., Pegoli W., Clemens M.G. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol. 266:1994;G624-G632
13. Kawada N., Tran-Thi T.A., Klein H., Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 213:1993;815-823
14. Rockey D.C., Fouassier L., Chung J.J., Carayon A., Vallee P., Rey C., et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology. 27:1998;472-480
15. Reichen J., Gerbes A.L., Steiner M.J., Sagesser H., Clozel M. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 28:1998;1020-1030
16. Kamath P.S., Tyce G.M., Miller V.M., Edwards B.S., Rorie D.K. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology. 30:1999;401-407
17. Graupera M., Garcia-Pagan J.C., Gonzalez-Abraldes J., Peralta C., Gomez G., Bragulat M., et al. Role of nitric oxide and cyclooxygenase products in the hyperesponse to methoxamine in cirrhotic rat liver. Hepatology. 34:2001;286A
18. Graupera M., Garcia-Pagan J.C., Pares M., Abraldes J.G., Rosello J., Bosch J., et al. Cyclooxyenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol. 39:2003;521
19. Graupera M., Garcia-Pagan J.C., Titos E., Claria J., Massaguer A., Bosch J., et al. 5-Lipoxygenase Inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 122:2002;387-393
20. Gupta T.K., Toruner M., Groszmann R.J. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. Digestion. 59:1998;413-415
21. Salmeron J.M., Ruiz A., Gines A., Garcia-Pagan J.C., Gines P., Feu F., et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology. 17:1993;800-806
22. Fiorucci S., Antonelli E., Morelli O., Mencarelli A., Casini A., Mello T., et al. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA. 98:2001;8897-8902
23. Loureiro-Silva M.R., Cadelina G.W., Iwakiri Y., Groszmann R.J. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol. 39:2003;940-946